Zentalis Pharmaceuticals, Inc.
ZNTL
$3.88
-$0.15-3.72%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -42.29M | -35.35M | -35.22M | -26.69M | -26.87M |
| Total Depreciation and Amortization | 153.00K | 151.00K | 157.00K | 160.00K | 160.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.17M | 2.97M | 5.50M | 738.00K | 334.00K |
| Change in Net Operating Assets | 1.73M | -728.00K | -1.38M | -1.17M | -8.33M |
| Cash from Operations | -37.24M | -32.96M | -30.94M | -26.96M | -34.71M |
| Capital Expenditure | 0.00 | -34.00K | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | 129.00K | 0.00 | 564.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 30.02M | 30.05M | 32.32M | 28.32M | 29.81M |
| Cash from Investing | 30.02M | 30.01M | 32.45M | 28.32M | 30.38M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 65.00K | 331.00K | 5.39M | 115.00K | 0.00 |
| Repurchase of Common Stock | 0.00 | -1.45M | -9.98M | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 65.00K | -1.12M | -4.59M | 115.00K | 0.00 |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -7.15M | -4.07M | -3.08M | 1.47M | -4.33M |